Privacy Statement

Effective Date: June 26, 2020

Adapt Pharma, Inc. respects the privacy of visitors to our websites, and as a result, we have developed this Online Privacy Statement (“Statement”). We may update this Statement from time to time, in which case we will revise the “Effective Date” above and post the new Statement on our websites.

SCOPE

This Privacy Statement applies only to the operation of websites that directly link to this Statement when you click on “Privacy Statement” in the website footer.

CONSENT TO PROCESSING IN THE UNITED STATES AND ELSEWHERE. This site is owned and operated by Adapt Pharma in the United States, but the information you provide may be accessible to our affiliates, vendors and suppliers in other countries. By using this site, you consent to the collection, storage and processing of your information in the United States and in any country to which we may transfer your information in the course of our business operations.

CATEGORIES OF INFORMATION COLLECTED

Contact Information. If you use our websites to request information from us, you may provide identifiers such as your name, address, telephone number, and email address.

Web Log Data. Our webservers collect internet or other electronic network activity, sometimes from cookies, web beacons, and similar technologies, when you visit one of our sites. The webserver automatically recognizes information such as your IP address, the date and time you visited our site, the pages you visited, the website you came from, the type of browser and operating system you are using, and the domain name and address of your Internet service provider.

Cookies and Other Technologies. We also collect internet or other electronic network activity information about your use of our sites through technology such as cookies and web beacons. A “web beacon” is a piece of code on our site that enables us to monitor things like user activity and site traffic. A “cookie” is a small file of letters and numbers that is stored on your browser or the hard drive of your computer. For more information about the cookies and similar technologies we deploy on our sites, please see the “COOKIES” section below.

By continuing to browse the site, you are agreeing to the use of cookies and similar technologies. If you do not agree to the use of cookies and similar technologies, please stop using the site immediately. 

Other Information You Provide. We may also collect any other information you choose to provide to us, including correspondence you send to us or recorded testimonials you submit regarding your use of our products.

We may combine this information with other data we may have about you as well as with data obtained from third parties, such as other users of our sites, advertising networks, operating systems and platforms, social networks, entities that sell data, government entities that make information publicly available, and other third-party services and organizations. For instance, if you access any social media or similar services through our sites to login or to share information about your experience on our sites with others, we may collect information from these third-party services. We may collect inferences based on the information described above and other information described in this Statement. We may aggregate or de-identify the information described above. Aggregated or de-identified data is not subject to this Statement.

HOW WE USE YOUR INFORMATION

We may use and otherwise process your information provided to our sites, including for the following business purposes:

  • Responding to your requests;
  • Sending you promotional materials from us or on behalf of us from our affiliates and third-party partners;
  • Analyzing the use of our sites to understand and improve them;
  • Customizing the content you see when you use our sites; and
  • Preventing potentially prohibited or illegal activities.

We may also use your information for any other purposes disclosed to you at the time we collect your information or pursuant to your consent.

HOW WE SHARE YOUR INFORMATION

We may disclose your information to third parties in certain cases:

  • Affiliated companies. We may share your information with our corporate affiliates.
  • Service providers. We may disclose your information to companies that provide services to us and our affiliated companies, such as companies that operate our sites on our behalf or for other business purposes such as customer service, market research, security and performance monitoring, data hosting, auditing, and data processing.
  • Legal purposes. We may disclose your information to a third party if it is necessary to comply with a legal obligation or the decision of a judicial authority, a public authority or a government body, or if disclosure is otherwise necessary to protect and defend the interests, safety, and security of Adapt Pharma, Inc., our affiliates, users, or the public.
  • Business transfers. If we make a sale or transfer of assets, or are otherwise involved in a merger or business or asset transfer, we may transfer your information to one or more third parties as part of that transaction.
  • Other third parties with your consent. We may also disclose your information to other third parties when you consent to such sharing.

We do not sell your personal information to third parties without your consent. We do disclose personal information for business purposes, including but not limited to services performed on our behalf, to protect against fraud and malicious activity, and to provide advertising on our sites and elsewhere based on users’ online activities over time and across different sites, services, and devices (so-called “interest-based advertising”). In addition, your information may be accessible to third parties with whom you interact or direct us to share your information through our sites. The information practices of these third parties are not covered by this Statement.

COOKIES

The following types of cookies are used on our sites:

  • Essential cookies. These are cookies that are required for the operation of the sites.
  • Analytical/performance cookies. These allow Adapt Pharma to recognize, count the number of visitors and see how visitors move around the sites when they are using it. This helps us to improve the way the sites work, for example, by ensuring that users are finding what they are looking for easily.
  • Functionality cookies. These are used to recognize you when you return to the sites.
  • Targeting cookies. These cookies record your visit to the sites, the pages you have visited and the links you have followed. Adapt Pharma may use this information to make the sites more relevant to your interests.

Third-Party Cookies and Advertising. Please note that third parties (including, for example, providers of external services such as web traffic analysis services, including Google Analytics) may also use cookies. These cookies are likely to be analytical/performance cookies or targeting cookies. We may partner with third-party ad networks to manage our advertising on other sites. Our ad network partners use cookies, web beacons, and similar technologies to collect information about your activities on this and other websites to provide you targeted advertising based upon your interests.

If you would like to opt-out of or manage cookies used for targeted advertising, you may do so by following the options provided by the Network Advertising Initiative at: http://www.networkadvertising.org/choices/ and the Digital Advertising Alliance at: http://www.aboutads.info/choices/. Please note that opting out of receiving targeted ads will not prevent you from being served advertisements generally. 

Digital Analytics. Our webserver will install a cookie on your machine in order to aid the accuracy of our data analytics program. We use information from this cookie to establish common web browsing of our users, such as links that have been clicked or documents accessed, which helps us to maintain and enhance the service we provide. This cookie will remain on your computer indefinitely, even after you leave our site.

Our sites use Google Analytics, a web analytics service provided by Google, Inc. (“Google”). Google Analytics uses cookies to help website operators analyze how users use the sites. Full details of the Google Analytics security and privacy principles can be found here. Full details of the Google Analytics security and privacy principles can be found here.

How to change your cookie settings. You have a variety of tools to control the data collected by cookies, web beacons, and similar technologies. For example, you can use controls in your internet browser to limit how the websites you visit are able to use cookies and to withdraw your consent by clearing or blocking cookies. To find out more about cookies, including how to see what cookies have been set and how to manage and delete them, visit www.aboutcookies.org or www.allaboutcookies.org.

Do Not Track. Some web browsers may transmit “do-not-track” signals to websites with which the browser communicates. We do not currently respond to these signals.

YOUR RIGHTS

Depending on where you live, you may be entitled, in accordance with applicable law, to request access to, deletion, or portability of your personal information. Requests should be submitted in writing to the address listed below in the “CONTACT INFORMATION” section or by clicking here. California residents can also submit requests by calling 855-894-4986. We will not discriminate against you for exercising your rights, although some of the functionality and features available on the sites may change or no longer be available to you. Any difference in the service or product requested are related to the value provided.

Once we receive your request, we may verify it by requesting information sufficient to confirm your identity. If you would like to use an authorized agent registered with the California Secretary of State to exercise your rights, we may request evidence that you have provided such agent with power of attorney or that the agent otherwise has valid written authority to exercise rights on your behalf.

CHILDREN

This site is not intended for or designed to attract individuals under the age of 18.

CONTACT INFORMATION

If you have any questions or comments about this Privacy Statement, please contact us by writing to:

Adapt Pharma, Inc.
401 Plymouth Road, Suite 400
Plymouth Meeting, PA 19462

INDICATION AND USAGE

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. Monitor for the development of opioid withdrawal.

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes.

Abrupt Postoperative Reversal of Opioid Depression: Abrupt postoperative reversal of opioid depression may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Serious sequelae of these events, including coma and death, have been reported. These events have primarily occurred in patients who had pre-existing cardiovascular (CV) disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone HCl.

Adverse Reactions: The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

NNS HCP ISI 08/2020

Please see full Prescribing Information.

References: 1. Opioid overdose. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/index.html. Accessed April 13, 2020. 2. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2020. 3. U.S. Surgeon General's advisory on naloxone and opioid overdose. U.S. Department of Health and Human Services website. https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html. Accessed April 14, 2020. 4. NARCAN® Nasal Spray [prescribing information]. Plymouth Meeting, PA: ADAPT Pharma, Inc.; 2020. 5. Mell HK, Mumma SN, Hiestand B. Emergency medical services response times in rural, suburban, and urban areas. JAMA Surg. 2017;152(10):983-984. 6. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245-252. 7. Management of substance abuse: information sheet on opioid overdose. World Health Organization website. http://www.who.int/substance_abuse/information-sheet/en. Updated August 2018. Accessed April 13, 2020. 8. Calculating total daily dose of opioids for safer dosage. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf. Accessed April 13, 2020. 9. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Chronic Pain – United States, 2016. Morb Mortal Wkly Rep. 2016;65(1):1-49. 10. National Safety Council. Prescription opioid pain killer public opinion poll. October 2017. 11. San Francisco Department of Public Health. Naloxone for opioid safety: a provider’s guide to prescribing naloxone to patients who use opioids. January 2015. https://prescribetoprevent.org/wp2015/wp-content/uploads/CA.Detailing_Provider_final.pdf. Accessed April 13, 2020.

INDICATION AND USAGE

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. Monitor for the development of opioid withdrawal.

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes.

Abrupt Postoperative Reversal of Opioid Depression: Abrupt postoperative reversal of opioid depression may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Serious sequelae of these events, including coma and death, have been reported. These events have primarily occurred in patients who had pre-existing cardiovascular (CV) disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone HCl.

Adverse Reactions: The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

NNS HCP ISI 08/2020

Please see full Prescribing Information.

References: 1. Opioid overdose. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/index.html. Accessed April 13, 2020. 2. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2020. 3. U.S. Surgeon General's advisory on naloxone and opioid overdose. U.S. Department of Health and Human Services website. https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html. Accessed April 14, 2020. 4. NARCAN® Nasal Spray [prescribing information]. Plymouth Meeting, PA: ADAPT Pharma, Inc.; 2020. 5. Mell HK, Mumma SN, Hiestand B. Emergency medical services response times in rural, suburban, and urban areas. JAMA Surg. 2017;152(10):983-984. 6. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245-252. 7. Management of substance abuse: information sheet on opioid overdose. World Health Organization website. http://www.who.int/substance_abuse/information-sheet/en. Updated August 2018. Accessed April 13, 2020. 8. Calculating total daily dose of opioids for safer dosage. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf. Accessed April 13, 2020. 9. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Chronic Pain – United States, 2016. Morb Mortal Wkly Rep. 2016;65(1):1-49. 10. National Safety Council. Prescription opioid pain killer public opinion poll. October 2017. 11. San Francisco Department of Public Health. Naloxone for opioid safety: a provider’s guide to prescribing naloxone to patients who use opioids. January 2015. https://prescribetoprevent.org/wp2015/wp-content/uploads/CA.Detailing_Provider_final.pdf. Accessed April 13, 2020.